She noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...

Regenerative Medicine Market Growth BURLINGAME, CA, UNITED STATES, February 14, 2025 /EINPresswire / --The global Regenerative Medicin ...

As the first first Novartis viral vector production facility in Europe, it significantly expands Novartis' research and ...

We recently compiled a list of the 13 Best Foreign Dividend Stocks To Buy According to Analysts. In this article, we are ...

Health Canada has approved Novartis Canada’s Fabhalta (iptacopan capsules) as the first oral monotherapy to treat adults with ...

The company provided 2025 guidance for TTR product sales of $1.6 billion to $1.725 billion, representing a 36% growth at the midpoint compared to 2024. This outlook assumes regulatory approval and the ...

A crucial challenge in AI today is bridging the gap between general intelligence and deep, organisation-specific knowledge.

In this process, royalty recipients often face the issue where multiple small future royalty streams cannot fulfill ongoing large lump-sum R&D funding needs. The mismatch is where Royalty Pharma ...

Alpha-synuclein inhibitors are a class of investigational therapies targeting the pathological aggregation of alpha-synuclein, a protein implicated i ...

Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress.